Crowle A J
Webb-Waring Lung Institute, University of Colorado Health Sciences Center, Denver.
Semin Respir Infect. 1986 Dec;1(4):262-4.
Testing new drugs or drug combinations for activity against tuberculosis is highly problematic: Clinical therapy trials are expensive and time-consuming; animal trial results may not be applicable to humans; and simple in vitro testing on culture medium excludes a vital component of the natural infection, namely the macrophage. Described here is a technique to treat with chemotherapy human macrophages that have been infected ex vivo with tubercle bacilli. Briefly discussed are the results of treating such infected phagocytes with a variety of agents: Streptomycin, ethambutol, pyrazinamide, isoniazid, and ceforanide. Interesting parallels between the macrophage-model results and observed clinical phenomena are noted. This model appears to have considerable potential for evaluating drug activity against tubercle bacilli, nontuberculous mycobacteria, and, perhaps, other intracellular parasites.
临床治疗试验成本高昂且耗时;动物试验结果可能不适用于人类;在培养基上进行的简单体外测试排除了自然感染的一个重要组成部分,即巨噬细胞。本文描述了一种用化疗方法处理已在体外感染结核杆菌的人类巨噬细胞的技术。简要讨论了用多种药物(链霉素、乙胺丁醇、吡嗪酰胺、异烟肼和头孢乙腈)处理此类感染吞噬细胞的结果。注意到巨噬细胞模型结果与观察到的临床现象之间有趣的相似之处。该模型在评估针对结核杆菌、非结核分枝杆菌以及可能的其他细胞内寄生虫的药物活性方面似乎具有相当大的潜力。